333
Participants
Start Date
August 24, 2018
Primary Completion Date
January 10, 2020
Study Completion Date
January 10, 2020
Semaglutide
Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
Novo Nordisk Investigational Site, Lund
Novo Nordisk Investigational Site, Bjärred
Novo Nordisk Investigational Site, Eslöv
Novo Nordisk Investigational Site, Staffanstorp
Novo Nordisk Investigational Site, Nybro
Novo Nordisk Investigational Site, Charlottenberg
Novo Nordisk Investigational Site, Örebro
Novo Nordisk Investigational Site, Sundsvall
Novo Nordisk Investigational Site, Søborg
Novo Nordisk Investigational Site, Avesta
Novo Nordisk Investigational Site, Ängelholm
Novo Nordisk Investigational Site, Åkersberga
Novo Nordisk Investigational Site, Bollnäs
Novo Nordisk Investigational Site, Falköping
Novo Nordisk Investigational Site, Flen
Novo Nordisk Investigational Site, Gothenburg
Novo Nordisk Investigational Site, Härnösand
Novo Nordisk Investigational Site, Helsingborg
Novo Nordisk Investigational Site, Huskvarna
Novo Nordisk Investigational Site, Karlskoga
Novo Nordisk Investigational Site, Kungsbacka
Novo Nordisk Investigational Site, Laholm
Novo Nordisk Investigational Site, Luleå
Novo Nordisk Investigational Site, Mölndal
Novo Nordisk Investigational Site, Nässjö
Novo Nordisk Investigational Site, Sala
Novo Nordisk Investigational Site, Stockholm
Novo Nordisk Investigational Site, Uddevalla
Novo Nordisk Investigational Site, Upplands Vasby
Novo Nordisk Investigational Site, Västerås
Lead Sponsor
Novo Nordisk A/S
INDUSTRY